A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population–Based Observational Data
Wang, Han I; Roman, Eve; Crouch, Simon; Aas, Eline; Burton, Cathy; Patmore, Russell; Smith, Alexandra Gwen;
Objectives To use real-world data to develop a flexible generic decision model to predict cost, life expectancy, and quality-adjusted life-years (QALYs) for follicular lymphoma (FL) in the general patient population. Methods All patients newly diagnosed with FL in the U... View more
Supplemental material accompanying this article can be found in the online version as a hyperlink at https://doi.org/10.1016/j.jval.
 Smith A, Roman E, Howell D, et al. The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol 2010;148:739-53.
 Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011;105:1684-92.
 Haematological Malignancy Research Network. HMRN 2018. https:// www.hmrn.org/statistics/incidence. [Accessed January 10, 2018].
 Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-andwait approach in patients with advanced-stage, asymptomatic, nonbulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 2014;15:424-35.
 van Agthoven M, Kramer MHH, Sonneveld P, et al. Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma. Haematologica 2005;90:1422-32.
 Beveridge R, Satram-Hoang S, Sail K, et al. Economic impact of disease progression in follicular non-Hodgkin lymphoma. Leuk Lymphoma 2011;52:2117-23.
 Wake B, Hyde C, Byran S, et al. Rituximab as third-line treatment for refractory or recurrent stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation. Health Technol Assess 2002;6:1-85.
 Hayslip JW, Simpson KN. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission. Clin Lymphoma Myeloma 2008;8:166-70.
 Hornberger J, Reyes C, Lubeck D, Valente N. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma 2008;49:227-36.